Compare Amgen, Inc. (AMGN) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Domino's Pizza, Inc. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Domino's Pizza, Inc. trades at $300.3 (market cap $9.96B). The key difference: Amgen, Inc. is far larger — about 19.7× Domino's Pizza, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | DPZ | |
|---|---|---|
Market Cap | $196.12B | $9.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $485.53 |
52-Week Low | $271.18 | $282.89 |
Enterprise Value | $241.41B | $14.86B |
Dividend Yield | 2.77% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Domino's Pizza (DPZ) trades at $299.46, down 0.47% on the day, near its 52-week low. The stock shows a bearish technical signal with support at $297 and resistance at $304. Fundamentally, revenue grew to $4.94B in 2025 with a net income margin of 11.89%, though recent quarters have seen earnings misses. The company maintains strong profitability but faces headwinds from slowing US sales growth and a CEO transition announced in June 2026.
The outlook is mixed: analyst consensus is bullish with a $380.31 price target, but near-term risks include competitive pressures and macroeconomic challenges. Long-term investors may find value at current levels given the company's market dominance and digital capabilities, though execution under new leadership and sales recovery are critical for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
